Tim Shannon has extensive biopharmaceutical operational experience leading product and business development for more than 15 years, and he was a practicing physician in pulmonary and critical care medicine. Tim joined Canaan in 2009 and brings strategic business sense as well as a hands-on medical and patient care perspective to Canaan's investments in biopharmaceuticals.
Tim was previously president and chief executive officer of CuraGen, a biopharmaceutical company focused on oncology. At CuraGen, he previously served as executive vice president of R&D and chief medical officer. Prior to CuraGen, he held positions of increasing responsibility for Bayer's Pharmaceutical Business Group including senior vice president of global medical development. He is a director at Celldex Therapeutics, which acquired CuraGen in October 2009, and is a member of the Quality Assurance, Compliance and Safety Committee for The Yale Cancer Center.
In addition to his operational experience, he was assistant professor of the pulmonary and critical care division at Yale University School of Medicine and an attending physician in pulmonary and critical care medicine at the West Haven V.A. Medical Center. Tim received his post graduate medical training at the Beth Israel Hospital of Harvard Medical School and at Boston University, earned his medical degree from the University of Connecticut, and has a B.A. in chemistry from Amherst College.